Why is Balaxi Pharma falling/rising?

As of 17-Nov, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs. 35.92, which reflects a decrease of Rs. 1.51 or 4.03%. The stock has hit a new 52-week low of Rs. 35.67 today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has underperformed its sector by 4.45%, and its returns have been significantly negative, with a 1-year return of -53.75%. The company's financial performance has also been troubling, with a -56.1% decline in profits over the past year, and a weak long-term fundamental strength indicated by a -4.77% CAGR growth in operating profits. Additionally, institutional investors have reduced their stake by 5.37%, reflecting a lack of confidence in the stock.
In the broader market context, Balaxi Pharmaceuticals has underperformed the benchmark, with a 1-week return of -13.90% compared to the Sensex's gain of 1.72%. This consistent underperformance against the benchmark over the last three years, coupled with negative financial results, has contributed to a lack of investor confidence. The stock's valuation, while attractive based on its price-to-book ratio, is overshadowed by its declining profits and weak operational metrics, leading to a perception of risk among investors. Overall, the combination of poor financial performance, declining institutional interest, and significant underperformance relative to the market has resulted in the stock's downward movement.